Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Dinutuximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Dinutuximab is an immunoglobulin G1κ monoclonal antibody that specifically targets the GD2 antigen. GD2 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. GD2 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Dinutuximab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to GD2 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.
Dinutuximab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), and 13-cis-retinoic acid (RA) to treat neuroblastoma in high-risk pediatric patients. Dinutuximab can also be used to treat melanoma
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.